Medical Xpress October 11, 2024
Ludwig Cancer Research

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses artificial intelligence algorithms to use its output to design personalized cancer vaccines for patients.

The design, validation and comparative assessment of this computational suite, NeoDisc, are detailed in the current issue of Nature Biotechnology in a publication led by Florian Huber and Michal Bassani-Sternberg of the Lausanne Branch of the Ludwig Institute for Cancer Research.

“NeoDisc provides unique insights into the immunobiology of tumors and the mechanisms by which they evade targeting by cytotoxic T cells of the immune system,” said Bassani-Sternberg.

“These insights are invaluable to the design of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Provider, Technology
Google digs deeper into healthcare AI: 5 notes
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
How AI Has And Will Continue To Transform Healthcare
AI Translates Nature into New Medicines | StartUp Health Insights: Week of Nov 26, 2024
Building AI trust: The key role of explainability

Share This Article